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INTRODUCTION
Parkinson’s disease (PD) is an example for a complex field of research, which is driven by the
multifactorial etiology, the heterogeneity in phenotype and the variability in disease progression,
as well as the presence of a long pre-diagnostic period, called prodromal PD, lasting up to decades
(Postuma et al., 2010). The very slow, so far inevitably progressive, neurodegenerative process and
the multidimensional heterogeneity of symptoms in kind (motor and non-motor), time of onset
and speed of progression call for prediction markers and progression markers to understand the
onset of neurodegeneration and its course. These markers would also help to establish endpoints
for neuroprotective treatment strategies aiming to modify disease progression. Because of the
complexity, heterogeneity, and the progressive nature of PD, such predictive and progression
markers can only be identified in large cohorts and in studies with a longitudinal design. A
considerable number of longitudinal cohort studies in PD patients, as well as in individuals at
risk, are currently being performed, and extensive effort has gone into the characterization of the
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individuals assessed. Although each study has its own value
and merits, many important research questions cannot be
answered as the numbers of participants are too small (e.g., when
studying conversion to PD in at-risk populations). Moreover,
the pivotal combination of data and findings across studies is
hampered by the lack of comparability of symptoms/factors
that are being assessed and the specific assessments that
are being applied. Therefore, a common approach is needed
to enable harmonization and combination of data across
studies to define and validate predictive and progression
markers.
Based on the need for harmonized assessments of
symptoms/markers in PD, the working group: Harmonization
of biomarker assessment in longitudinal cohort studies in
Parkinson’s Disease (BioLoC-PD) of the Joint Programme
for Neurodegenerative Diseases (JPND), set out to develop
an assessment battery that includes the most useful clinical,
laboratory, and brain imaging assessments for (longitudinal)
studies in PD.
We here describe the result of the process to find a way to
harmonize assessments across studies and propose a modular set
of biomarker assessments agreed upon by the group of experts
who were included in the working group (all authors of this
manuscript).
MATERIALS AND METHODS
As a first step, information about the design, markers, and
assessments of 21 ongoing cohort studies in various phases of
PD represented by members of the JPND working group were
collected using a detailed questionnaire. These data served as
a basis for the project. Detailed results have been reported
previously in Lerche et al. (2015). In a second step, a systematic
literature search on assessments and markers in the prodromal
and clinical phases of PD was conducted to determine the most
useful predictive and progression markers in PD. The outcome of
this literature search was combined with the study information
derived from the BioLoC-PD studies and the expert clinical
knowledge of the principal investigators in their clinical routine.
This information were used to establish the proposed assessment
battery. A common modular set of biomarker assessments was
defined that includes a basic module and different modules for
extension, in order to account for the differences in research focus
between studies.
Abbreviations: ADL, Activities of daily living; BDI-II, Beck depression inventory
version II; CSF, Cerebrospinal fluid; I123-FP-CIT, 123I-N-ω-fluoropropyl-
2β-carbomethoxy-3β-(4-iodophenyl)nortropane); DNA, Deoxyribonucleic
acid; FDG-PET, fluorodeoxyglucose positron emission tomography; fMRI,
functional magnetic resonance imaging; GDS, Geriatric depression scale; HAAS,
Honolulu Asia Aging study, MDS-UPDRS, Movement Disorder Society—Unified
Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination;
MoCA, Montreal Cognitive Assessment; MRI magnetic resonance imaging; PD,
Parkinson’s Disease; PDQ-39, Parkinson’s Disease Questionnaire-39 items; QoL,
Quality of Life; RBD-SQ, Rapid eye movement sleep behavior disorder screening
questionnaire; RNA, Ribonucleic acid; SCOPA, Scales for Outcome in Parkinson’s
Disease; TCS, transcranial sonography.
RESULTS
Composition of a Modular Set of
Biomarker Assessments
Based on the analyses, the JPND BioLoC-PD working group
suggests the following three-level modular assessment battery
to be implemented in new and whenever possible ongoing
longitudinal studies for PD (Figure 1). The set comprises a
basic module (demographics, diagnosis, etc.), a minimum
function and assessment module and several optional extension
modules.
The basic module is meant to be applied to all participants
in longitudinal studies in PD. It may also be applied to
existing registers and patients seen routinely in outpatient
clinics irrespective of whether they are currently recruited for
a longitudinal study. It may also be used for retrospective
analyses or identification of potential eligible participants for
future randomized controlled trials.
The minimum module is suitable for all individuals
participating in at risk, prodromal, and clinical longitudinal
studies of PD. The functions of the minimum module are in
a descending order (sorted by their use within the BioLoC-PD
working group). Functions used in all (risk, prodromal, and
clinical) PD studies are at the beginning of each of the lists (in
the minimum and extension modules). Modes of assessment of
these symptoms are based on the frequency and applicability
within studies (easy to apply assessments, which still provide
sufficient information were preferred). Each of the assessments
suggested for the minimum module (Figure 1) takes no more
than 10 min, depending on the cognitive capacity of the study
participant. For some functions (neuropsychiatric and olfactory),
two optional assessments are suggested from which one can be
chosen. This is because they are used in almost equal proportion
in ongoing studies and are similarly tolerable for the participants.
For the neuropsychiatric function we recommend to use the BDI
in prodromal studies and in early stage PD studies and the GDS
in late stage PD studies. For olfaction two assessments are given
because they are used in almost equal proportion in ongoing
studies are similarly tolerable for the participants. However, the
first mentioned suggestion, is slightly preferred by the BioLoC-
PD consortium (used more often). Regarding the use of the
MMSE or MoCA, we found that the MMSE is more often applied
in existing studies but for new studies we clearly recommend to
use the MoCA.
The optional extension module can be applied to evaluate
study participants in more detail. The selection of the additional
function modules depends on the main research focus of
the study, on the number of study participants and on
the available staff and finance. Optional modules can be
applied to interesting sub-groups of participants, if financial or
pragmatic/practical factors hinder administration to the whole
cohort. The assessments included in the extension modules
were chosen based on their implementation in the ongoing
BioLoC-PD studies. For each subdomain within the extension
modules, the most commonly used assessment is suggested
in addition to the minimum module (e.g., motor→gait and
balance→accelerometer). In case of the imaging module the
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FIGURE 1 | Suggestion for a modular set of biomarker assessments to be used in longitudinal studies in PD. The number of studies using the assessment
in the BioLoC-PD consortium are given in brackets.
methods are in a descending order with the one on the top
preferred by the BioLoC-PD consortium.
Application of the Modular Set of
Biomarker Assessments
We propose, that each study should as a minimum requirement
collect the data specified in the basic module. The basic module
is valuable also for genetic or other non-clinical analyses. Once
individuals are clinically examined, several motor and non-
motor domains should be covered, as suggested in the minimum
module which also comprises additional data about medical
history. Finally, according to the main research aim of the study,
different extension modules can be added.
In general, we provide researchers with suggestions for
specific assessment tools/scales to allow comparison across
studies. For the cognition module, however, it is less important
which assessments are used rather, it is important to take a
minimum of two tests per domain for a sensitive and specific
diagnosis of dementia and Mild Cognitive Impairment (MCI)
level II (Goldman et al., 2015). For cognitive analyses, a
comparison of studies with different assessments will then be
possible by comparing the domain z-scores (Aarsland et al.,
2010), equipercentile or item response theory modeling or by
using existing conversion algorithms (e.g., conversion between
the MMSE and MOCA tests (Lawton et al., 2016)). A list
of neuropsychological tests suitable for the optional cognitive
extension module can be found in Goldman et al. (2015) and
Litvan et al. (2012).
DISCUSSION
The inventory of assessments used in ongoing longitudinal
studies within the working group revealed that there is a
consensus about the functions/domains that should be assessed
in PD cohort studies, but not about the nature of specific
assessments used. The variability in the choice of the assessments
may be explained by a number of different factors: (i) Not all
scales/questionnaires are available and validated in all languages.
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(ii) Study designs vary with regard to outcome variables which
influences the choice of assessments. (iii) Some assessments
require more resources than others (more time-consuming, more
costly or requiring trained staff members), which also influenced
the selection and composition of the selected assessment battery.
(iv) Advances in knowledge about assessments and biomarkers
have led to revision or expansion of assessments after the
respective study was initiated. (v) Preference for a specific
assessment based on previous experience of the individual
researchers involved.
With our proposed modular set of biomarker assessments, we
propose a concept by which we hope to overcome the problem of
data comparison due to lack of harmonization and set the stage
for broad data sharing, joint data analyses and acceleration of
biomarker research.
AUTHOR CONTRIBUTIONS
SL, SH, GA, PB, SB, YBS, HB, BRB, DBu, RD, DG, GH, MH, MK,
RK, ILS, WM, MM, BM, WO, BR, UW, KW, DBe substantial
contributed to the conception and design of the work; SL, SH,
DBe drafted the work; GA, PB, SB, YBS, HB, BRB, DBu, RD,
DG, GH, MH, MK, RK, ILS, WM, MM, BM, WO, BR, UW, KW
revised the work critically for important intellectual content; SL,
SH, GA, PB, SB, YBS, HB, BRB, DBu, RD, DG, GH, MH, MK,
RK, ILS, WM, MM, BM, WO, BR, UW, KW, DBe gave their final
approval to the version to be published; SL, SH, GA, PB, SB, YBS,
HB, BRB, DBu, RD, DG, GH, MH, MK, RK, ILS, WM, MM, BM,
WO, BR, UW, KW, DBe agreed to be accountable for all aspects
of the work.
FUNDING
The work was funded by the EU Joint Programme—
Neurodegenerative Disease Research (JPND) program (BMBF
No:01ED1410).
ACKNOWLEDGMENTS
We acknowledge support of publication by Deutsche
Forschungsgemeinschaft and Open Access Publishing Fund
of Tuebingen University, Tuebingen, Germany.
REFERENCES
Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K.,
Kulisevsky, J., et al. (2010). Mild cognitive impairment in Parkinson
disease: a multicenter pooled analysis. Neurology 75, 1062–1069. doi:
10.1212/WNL.0b013e3181f39d0
Goldman, J. G., Holden, S., Ouyang, B., Bernard, B., Goetz, C. G., and
Stebbins, G. T. (2015). Diagnosing PD-MCI by MDS Task Force criteria: how
many and which neuropsychological tests? Mov. Disord. 30, 402–406. doi:
10.1002/mds.26084
Lawton, M., Kasten, M., May, M. T., Mollenhauer, B., Schaumburg, M., Liepelt-
Scarfone, I., et al. (2016). Validation of conversion between mini-mental state
examination andmontreal cognitive assessment.Mov. Disord. 31, 593–596. doi:
10.1002/mds.26498
Lerche, S., Liepelt-Scarfone, I., Alves, G., Barone, P., Behnke, S., Ben-Shlomo,
Y., et al. (2015). Methods in neuroepidemiology characterization of European
Longitudinal Cohort Studies in Parkinson’s Disease - Report of the JPND
Working Group BioLoC-PD.Neuroepidemiology 45, 282–297. doi: 10.1159/000
43922
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D.,
Petersen, R. C., et al. (2012). Diagnostic criteria for mild cognitive
impairment in Parkinson’s disease: Movement Disorder Society
Task Force guidelines. Mov. Disord. 27, 349–356. doi: 10.1002/mds.
24893
Postuma, R. B., Gagnon, J. F., and Montplaisir, J., (2010). Clinical prediction
of Parkinson’s disease: planning for the age of neuroprotection. J.
Neurol. Neurosurg. Psychiatry 81, 1008–1013. doi: 10.1136/jnnp.2009.
174748
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Lerche, Heinzel, Alves, Barone, Behnke, Ben-Shlomo, Berendse,
Bloem, Burn, Dodel, Grosset, Hipp, Hu, Kasten, Krüger, Liepelt-Scarfone, Maetzler,
Moccia, Mollenhauer, Oertel, Roeben, Walter, Wirdefeldt and Berg. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 4 May 2016 | Volume 8 | Article 121
